Cerus CERS Stock Price, News & Info The Motley Fool
This suggests a possible upside of 188.5% from the stock’s current price. View analysts price targets for CERS or view top-rated stocks among Wall Street analysts. Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma.
- Late that day, S&P Dow Jones Indices — operator of the high-profile indexes that bear the S&P name — effected its typical quarterly rebalance of several indexes.
- After all, being listed barely impacts a company’s fundamentals, if at all.
- The firm produces blood system for platelets and plasma.
- Upgrade to MarketBeat All Access to add more stocks to your watchlist.
This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher… Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. A positive regulatory development sent Cerus’ shares higher today.
Cerus has been notified by Fresenius Kabi of pending US supply shortage of platelet additive solution
The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals. Unique to Barchart.com, Opinions analyzes a stock or commodity matrix organizations are really a combination of the using 13 popular analytics in short-, medium- and long-term periods. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA. Unfortunately for shareholders of Coherus BioSciences (CHRS 1.28%), that’s what happened to their company after market hours last Friday. Following that, its stock price was falling by 10% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence.
Cerus Corporation Announces Multi-Year Contract for the INTERCEPT Blood System for Platelets with the American Red Cross
Live by the index, die by the index — being included in a well-known collection of stocks can really help a company’s visibility and boost investor morale. The opposite effect can kick in if it gets kicked out of an index. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Cerus’ stock is owned by many different retail and institutional investors.
- Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.
- The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals.
- Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
- You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.
Since then, CERS shares have decreased by 53.7% and is now trading at $1.69. Data are provided ‘as is’ for informational purposes https://1investing.in/ only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.
Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for Cerus and its competitors with MarketBeat’s FREE daily newsletter.
Investors headed for the exits after the company announced an unexpected product supply shortage. The company provided an update on the most pressing issue facing the biopharma stock in 2017. A better-than-expected outlook after the company’s first-quarter report is lifting more than spirits.
the Cerus stock price / share price today?
The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $160.00 million-$165.00 million, compared to the consensus revenue estimate of $172.56 million. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Eric Volkman has no position in any of the stocks mentioned. While the “index effect” often occurs with stock inclusion or deletion from a popular index, it tends to be short-lived. After all, being listed barely impacts a company’s fundamentals, if at all. But getting the boot means that a stock can fall off the radar of the many index funds that comb such collections for investment opportunities. The changes, which also affect the bellwether large-cap S&P 500 index, will take effect before market open on Monday, Sept. 18.
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month.
The popular growth investor publishes her daily transactions. Cathie Wood keeps buying Tesla as well as some of her smaller holdings. Positive pivotal trial results bode well for the company’s new blood transfusion product. Preliminary third-quarter results pleased the crowd at the company’s annual investor meeting. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.
3 brokers have issued 12-month price targets for Cerus’ shares. Their CERS share price forecasts range from $3.75 to $6.00. On average, they expect the company’s share price to reach $4.88 in the next twelve months.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. 3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Cerus in the last year.